Nov 7 Statement | UMR Congratulates Dr. Monica Bertagnolli on her Confirmation as the next NIH Director
NIH Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
2023 Rural State Analysis | UMR's Newest Report Reveals the Exponential Impact of NIH Research Funding in Rural States
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

Pfizer, J&J urge clarity from FDA on future of COVID-19 vaccine trials once a vaccine is available

Pfizer Inc and Johnson & Johnson are seeking input from a U.S. Food and Drug Administration advisory committee on retaining and attracting volunteers for COVID-19 vaccine trials after a vaccine becomes available, if they know they might receive a placebo. Both U.S. companies are among a handful with pivotal, late-stage COVID-19 vaccine trials underway.

The comments in letters ahead of the meeting of expert advisers on Thursday underscore dilemmas facing leading coronavirus vaccine developers and those whose large trials are just beginning or being planned.